|drug3027||Saline oral/nasal rinse Wiki||1.00|
|drug5||0.12% Chlorhexidine oral/nasal rinse Wiki||1.00|
|drug6||0.5% Povidone/Iodine oral/nasal rinse Wiki||1.00|
|D041881||Cholecystitis, Acute NIH||1.00|
There is one clinical trial.
The ChoCO (Cholecystitis under COVID-19 pandemic) STUDY PROTOCOL Gangrenous cholecystitis is the most common complication of acute cholecystitis, affecting around 15% (range 2-30%) of patients and it occurs as a result of ischemia with necrosis of the gallbladder wall. Preliminary data showed that COVID-19 patients have a high risk to present necrotic cholecystitis. Our aim is to investigate risk factors related to develop necrotic cholecystitis in COVID-19 negative and positive patients carrying out a multicentric prospective observational study.
Description: Our hypothesis is that COVID-19 patients should not treated conservatively (antibiotics only/ percutaneous drainage of gallbladder for the high risk of progressing to necrotic and then perforated cholecystitis. It was reported that COVID-19 disease predisposes to both venous and arterial thromboembolism, explained by excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation. In particular, critically ill patients with SARS-CoV-2 showed a high risk to present a thromboembolic events.Measure: Risk factors for necrotic cholecystitis in COVID-19 patients Time: 6 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports